New safety data for leukemia drug BESPONSA in 421 patients
NCT ID NCT05923112
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 25 times
Summary
This study looked at the safety and side effects of the drug BESPONSA in 421 adults whose acute lymphocytic leukemia had come back or stopped responding to treatment. All participants received BESPONSA as prescribed by their doctor. The main goal was to track serious side effects, especially liver problems and low blood counts. This is not a cure, but a way to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.